The primary efficacy outcome occurred in @ of @ patients ( @ % ) who received the @-mg dose of FXI-ASO and in @ of @ patients ( @ % ) who received the @-mg dose of FXI-ASO , as compared with @ of @ patients ( @ % ) who received enoxaparin .